An Accidental Clue in a Dish of Pituitary Cells: Cyril Bowers and the Road to Ipamorelin

In science, an experiment that behaves strangely is either a nuisance or the start of something. In the 1970s, a researcher at Tulane University named Cyril Bowers had one of the strange ones, and he decided not to ignore it.

The setup

Bowers was a pioneer of hypothalamic hormones, and his laboratory used a method that was ingenious in its simplicity: dispersed rat pituitary cells in culture. Instead of testing a compound in an animal, with all the complexity of blood, brain and feedback loops, you could drop it on isolated pituitary cells and measure how much growth hormone they released into the medium. Growth hormone secretion in a dish is a clean readout, and a screen could be run on many compounds.

At the time, the known stimulator of growth hormone release was growth hormone-releasing hormone, GHRH, a peptide made in the hypothalamus. Its structure had been worked out in the early 1980s, and Bowers’s lab was working in the same neighborhood of questions.

The accident

The clue came from an unexpected direction: opioid peptides. Enkephalins, the body’s own morphine-like peptides, were hot topics in the 1970s. Researchers noticed that certain enkephalin-related compounds seemed to affect hormone release in animals. Bowers and colleagues tested analogs of enkephalin on pituitary cells and found that some of them stimulated growth hormone release directly.

Here was the puzzle: the effect was not blocked by naloxone, the standard opioid antagonist. So the compounds were not acting through opioid receptors. They were hitting something else on the pituitary cells. In effect, a chemical designed in one context had accidentally revealed a new receptor system.

Bowers’s team followed the lead with systematic chemistry. By altering residues, particularly introducing D-amino acids, they steadily improved potency. In the mid-1980s they described GHRP-6, a hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, which released growth hormone potently both in cultured cells and in animals, and later in people in clinical research. The family became known as growth hormone-releasing peptides, or GHRPs, or more broadly growth hormone secretagogues.

A receptor looking for its ligand

The next chapter belongs to the story of the receptor. For about a decade, the GHRPs were drugs without a known target. Merck and others developed nonpeptide molecules with the same effect. In 1996, researchers cloned the receptor that these compounds activate, a G-protein-coupled receptor now called GHS-R1a. And then came the twist that earned the field its place in textbooks: the natural hormone for that receptor had not yet been found. When researchers in Japan, led by Masayasu Kojima, finally purified it in 1999 from stomach tissue, they named it ghrelin. A chance observation with enkephalin analogs had pointed to a hormone nobody knew existed, and the receptor was identified before its natural ligand.

Ipamorelin: a more selective design

The first-generation GHRPs had a drawback that attracted attention in research: in addition to growth hormone, some of them also raised ACTH and cortisol and, to a lesser degree, prolactin. The stress-hormone effect was a complication for anyone wanting to study growth hormone release cleanly.

In the late 1990s, scientists at Novo Nordisk published a pentapeptide called ipamorelin (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂), designed to keep the growth hormone release while minimizing the other pituitary responses. Their reports, including studies in rats and swine and early clinical research, described ipamorelin as releasing growth hormone with relatively little effect on ACTH and cortisol at the doses tested. This selectivity is the main reason ipamorelin is discussed in the research literature as a cleaner tool compared with earlier secretagogues.

Why combine it with a GHRH analog?

Bowers made another observation that explains the logic behind combination products. When a GHRP and GHRH are given together, the growth hormone release is greater than the sum of what each produces alone. This is called synergy, and it makes biological sense: the two peptides act on different receptors, GHS-R1a and the GHRH receptor, and their downstream pathways converge in the somatotroph cell. GHRH raises cAMP, the GHRP engages calcium and protein kinase C signaling, and ghrelin-type signals also modulate the hypothalamus itself, including by reducing the inhibitory influence of somatostatin.

CJC-1295 (in its unmodified form, sometimes called modified GRF 1-29) is a GHRH analog with several amino acid substitutions designed to resist enzymatic cleavage, a theme you will recognize from other peptide design stories. Pairing it with a ghrelin-receptor agonist is the natural way to study the synergy in a single experiment.

Lessons for the bench

1. Synergy needs proper testing. A claim that two compounds are synergistic requires single-agent arms and a formal analysis against an additivity model, not just a larger effect.
2. Selectivity must be measured. If a compound is said to be selective, check what was measured. ACTH, cortisol and prolactin readouts are the relevant controls here.
3. Species and assay matter. Rat pituitary cells, intact rats, swine and humans differ in secretagogue responsiveness.
4. Pulsatility is a design variable. Growth hormone is released in pulses, and sampling frequency determines what you can see.

Bowers’s story is a reminder that big fields can begin with a failed control, and that careful attention to what did not happen, here, naloxone failing to block the effect, can matter as much as what did.

For researchers studying these two pathways together, specifications and batch documentation are on the CJC-1295 + Ipamorelin Blend product page.

All Lucid Aminos products are sold strictly for laboratory research use. They are not drugs, dietary supplements or food, and they are not for human or veterinary use. This article is a historical and educational account and is not medical advice.